Histopathological analysis indicated that the tumor shrinkage induced by the trametinib/αPD-1 combination was associated with a massive infiltration and accumulation of activated CD8+ T cells, as determined by granzyme B and CD8 staining (figure 3F). This evidence concerns the gene CD8A and neoplasm.